Healing of erosions in rheumatoid arthritis remains elusive: results with 24 months of the anabolic agent teriparatide.

Duryea J, Gravallese EM, Wortman JR, Xu C, Lu B, Kay J, Solomon DH

Scandinavian journal of rheumatology6 Aug 2020Cited by 3 (Europe PMC)

PMID32757870DOI10.1080/03009742.2020.1772362PepBankPUB-32757870

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

01HumanNon-randomized trialEfficacy outcome
In patients with rheumatoid arthritis, MCP erosion volume changes were similar after 24 versus 12 months of teriparatide.
In plain wordsIn patients with rheumatoid arthritis, MCP erosion changes were similar with 24 versus 12 months of teriparatide.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeMCP erosion volume by treatment duration
Study
n = 11
Comparator
12 months of teriparatide
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 24 monthsAs given in this study (human).
Source sentences
Summary
The six subjects who received 24 months of TPTD had similar changes in erosion volume to the five who received 12 months of TPTD, in MCP (p = 0.17) and PIP (p = 0.63) joints.
1 context sentence(design, population, supporting numbers)
Summary · context
Subjects in a previous 12 month randomized controlled trial of TPTD in RA were invited to receive 12 additional months of open-label TPTD.
Report a problemFND-3275787003
02HumanNon-randomized trialEfficacy outcome
In patients with rheumatoid arthritis, PIP erosion volume changes were similar after 24 versus 12 months of teriparatide.
In plain wordsIn patients with rheumatoid arthritis, PIP erosion changes were similar with 24 versus 12 months of teriparatide.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changePIP erosion volume by treatment duration
Study
n = 11
Comparator
12 months of teriparatide
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 24 monthsAs given in this study (human).
Source sentences
Summary
The six subjects who received 24 months of TPTD had similar changes in erosion volume to the five who received 12 months of TPTD, in MCP (p = 0.17) and PIP (p = 0.63) joints.
1 context sentence(design, population, supporting numbers)
Summary · context
Subjects in a previous 12 month randomized controlled trial of TPTD in RA were invited to receive 12 additional months of open-label TPTD.
Report a problemFND-3275787004
03HumanNon-randomized trialEfficacy outcome
In patients with rheumatoid arthritis, MCP erosion volume did not change significantly from baseline after 24 months of teriparatide.
In plain wordsIn patients with rheumatoid arthritis, finger-joint erosion volume did not change significantly from baseline after 24 months of teriparatide.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeMCP erosion volume versus baseline
Study
n = 6
Comparator
baseline
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 24 monthsAs given in this study (human).
Source sentences
Summary
In the six patients who received 24 months of TPTD, there was no significant change in erosion volume at the metacarpophalangeal (MCP) and proximal interphalangeal (PIP) joints compared with baseline.
1 context sentence(design, population, supporting numbers)
Summary · context
Subjects in a previous 12 month randomized controlled trial of TPTD in RA were invited to receive 12 additional months of open-label TPTD.
Report a problemFND-3275787001
04HumanNon-randomized trialEfficacy outcome
In patients with rheumatoid arthritis, PIP erosion volume did not change significantly from baseline after 24 months of teriparatide.
In plain wordsIn patients with rheumatoid arthritis, PIP joint erosion volume did not change significantly from baseline after 24 months of teriparatide.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changePIP erosion volume versus baseline
Study
n = 6
Comparator
baseline
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 24 monthsAs given in this study (human).
Source sentences
Summary
In the six patients who received 24 months of TPTD, there was no significant change in erosion volume at the metacarpophalangeal (MCP) and proximal interphalangeal (PIP) joints compared with baseline.
1 context sentence(design, population, supporting numbers)
Summary · context
Subjects in a previous 12 month randomized controlled trial of TPTD in RA were invited to receive 12 additional months of open-label TPTD.
Report a problemFND-3275787002
05HumanNon-randomized trialEfficacy outcome
In patients with rheumatoid arthritis, large erosions showed no evidence of healing after 24 months of teriparatide.
In plain wordsIn patients with rheumatoid arthritis, large erosions showed no healing after 24 months of teriparatide compared with baseline.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeLarge erosion healing
Study
n = 6
Comparator
baseline
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 24 monthsAs given in this study (human).
Source sentences
Summary
Assessment of large erosions in those receiving TPTD for 24 months showed no evidence of erosion healing.
1 context sentence(design, population, supporting numbers)
Summary · context
Subjects in a previous 12 month randomized controlled trial of TPTD in RA were invited to receive 12 additional months of open-label TPTD.
Report a problemFND-3275787005

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.